Published in Endocrinology on January 10, 2012
Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol (2013) 1.63
Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension. Hypertension (2013) 1.52
A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. Am J Physiol Heart Circ Physiol (2012) 1.14
Metabolic rate regulation by the renin-angiotensin system: brain vs. body. Pflugers Arch (2012) 0.99
Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity. J Neurosci (2013) 0.97
Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem (2013) 0.97
Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol (2013) 0.97
Mechanisms of Cachexia in Chronic Disease States. Am J Med Sci (2015) 0.84
Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension. Am J Physiol Regul Integr Comp Physiol (2015) 0.83
Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration. J Biol Chem (2014) 0.82
Research on cachexia, sarcopenia and skeletal muscle in cardiology. J Cachexia Sarcopenia Muscle (2012) 0.81
Skeletal muscle protein metabolism in human heart failure. Curr Opin Clin Nutr Metab Care (2013) 0.81
Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function. Skelet Muscle (2014) 0.80
Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Br J Pharmacol (2015) 0.79
RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches. Cardiorenal Med (2012) 0.78
Angiotensin II Type 1 Receptor-Dependent GLP-1 and PYY Secretion in Mice and Humans. Endocrinology (2016) 0.76
Appetite regulation is independent of the changes in ghrelin levels in pregnant rats fed low-protein diet. Physiol Rep (2015) 0.76
An Intronic Enhancer Element Regulates Angiotensin II Type 2 Receptor Expression during Satellite Cell Differentiation, and Its Activity Is Suppressed in Congestive Heart Failure. J Biol Chem (2016) 0.75
Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome. J Transl Int Med (2016) 0.75
THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES. Trans Am Clin Climatol Assoc (2016) 0.75
Central TrkB blockade attenuates ICV angiotensin II-hypertension and sympathetic nerve activity in male Sprague-Dawley rats. Auton Neurosci (2017) 0.75
Central nervous system control of food intake. Nature (2000) 15.85
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature (2004) 7.64
Biology of cachexia. J Natl Cancer Inst (1997) 4.18
Mechanisms of cancer cachexia. Physiol Rev (2009) 4.03
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest (2007) 3.32
Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol (2005) 2.66
Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett (1994) 2.65
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J (2000) 2.45
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest (2005) 2.24
Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis (2007) 2.21
AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med (2008) 2.16
Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol (2008) 2.15
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation (2005) 1.92
Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer (1997) 1.88
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
Role of neuronal energy status in the regulation of adenosine 5'-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior. Endocrinology (2004) 1.87
Role of neuropeptides in appetite regulation and obesity--a review. Neuropeptides (2006) 1.67
Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol (1997) 1.65
Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest (1996) 1.54
Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology (2005) 1.54
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest (2009) 1.51
Cardiac cachexia: a systematic overview. Pharmacol Ther (2008) 1.49
Anorexia during acute and chronic disease. Nutrition (1996) 1.48
Activation/deactivation of renal Na+,K(+)-ATPase: a final common pathway for regulation of natriuresis. FASEB J (1994) 1.39
Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity. Diabetologia (2006) 1.37
Characterisation of 5'-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5'-AMP analogues on enzyme activity. Biochem Biophys Res Commun (1994) 1.37
The syndrome of cardiac cachexia. Int J Cardiol (2002) 1.33
Neuropeptides, food intake and body weight regulation: a hypothalamic focus. Peptides (2002) 1.33
Hypothalamic control of energy balance: different peptides, different functions. Peptides (2004) 1.31
Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med (2005) 1.27
Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology (2001) 1.24
Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun (2007) 1.24
Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation (2004) 1.23
Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ Res (2001) 1.22
IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol (2010) 1.17
Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem (2008) 1.12
Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol (2002) 1.11
Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun (2011) 1.07
Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens (1999) 1.04
Angiotensin II as candidate of cardiac cachexia. Curr Opin Clin Nutr Metab Care (2006) 1.04
Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int (1993) 1.00
Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling. Hypertension (2008) 0.98
Immunoregulators in the nervous system. Neurosci Biobehav Rev (1991) 0.97
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol (1998) 0.97
The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology (2009) 0.95
AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats. Neurosci Lett (2011) 0.93
Angiotensin II type 1 receptor signaling regulates feeding behavior through anorexigenic corticotropin-releasing hormone in hypothalamus. J Biol Chem (2011) 0.92
Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr Res (2006) 0.92
Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension (2011) 0.90
Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res (1998) 0.90
Neural networks of several novel neuropeptides involved in feeding regulation. Nutrition (2008) 0.87
ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin (2009) 0.85
Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin (2011) 0.85
Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol (1998) 0.85
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? J Am Board Fam Med (2009) 0.81
The value of current interventions for obesity. Nat Clin Pract Cardiovasc Med (2008) 0.81
Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm (2000) 0.80
Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? J Renin Angiotensin Aldosterone Syst (2005) 0.79
From genetics to mechanism of disease liability. Adv Genet (2008) 0.78
Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag (2009) 0.77
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol (2013) 1.72
Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J Mol Cell Cardiol (2011) 1.69
The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens (2011) 1.44
Digital plethysmography and arginine metabolism in prehypertension: effect of nebivolol therapy. J Clin Hypertens (Greenwich) (2014) 1.38
Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol (2007) 1.35
WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal (2010) 1.28
Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail (2008) 1.28
Enhancing repair of the mammalian heart. Circ Res (2007) 1.21
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep (2013) 1.20
IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol (2010) 1.17
Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci (2012) 1.16
Effect of Hurricane Katrina on incidence of acute myocardial infarction in New Orleans three years after the storm. Am J Cardiol (2011) 1.13
Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol (2010) 1.11
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol (2010) 1.11
A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J Lipid Res (2005) 1.09
Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun (2011) 1.07
Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci (2011) 1.06
Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol (2003) 1.06
EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol (2010) 1.05
Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal (2011) 1.05
Effect of Hurricane Katrina on the incidence of acute coronary syndrome at a primary angioplasty center in New Orleans. Disaster Med Public Health Prep (2009) 1.03
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab (2010) 0.99
Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem (2013) 0.97
Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol (2013) 0.97
Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol (2012) 0.96
Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J Cell Physiol (2011) 0.96
Insulin-like growth factor-1 increases synthesis of collagen type I via induction of the mRNA-binding protein LARP6 expression and binding to the 5' stem-loop of COL1a1 and COL1a2 mRNA. J Biol Chem (2014) 0.95
Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure. J Card Fail (2011) 0.94
Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One (2012) 0.93
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling. Free Radic Biol Med (2013) 0.92
Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. J Am Coll Cardiol (2004) 0.92
Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system. Am J Physiol Regul Integr Comp Physiol (2008) 0.91
Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol (2014) 0.91
Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension (2011) 0.90
Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice. Am J Physiol Heart Circ Physiol (2011) 0.90
Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90. Biochim Biophys Acta (2010) 0.89
Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology (2005) 0.89
Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol (2005) 0.89
Predictors of left ventricular dilatation in young adults (from the Bogalusa Heart Study). Am J Cardiol (2006) 0.88
Interleukin-18 enhances IL-18R/Nox1 binding, and mediates TRAF3IP2-dependent smooth muscle cell migration. Inhibition by simvastatin. Cell Signal (2013) 0.87
β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. J Mol Cell Cardiol (2011) 0.87
Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology (2009) 0.87
Brain heterotrimeric Gαi₂-subunit protein-gated pathways mediate central sympathoinhibition to maintain fluid and electrolyte homeostasis during stress. FASEB J (2012) 0.86
Tonic nociceptinergic inputs to neurons in the hypothalamic paraventricular nucleus contribute to sympathetic vasomotor tone and water and electrolyte homeostasis in conscious rats. J Pharmacol Exp Ther (2006) 0.86
Hypothalamic paraventricular nucleus G alpha q subunit protein pathways mediate vasopressin dysregulation and fluid retention in salt-sensitive rats. Endocrinology (2010) 0.85
Insulin-like growth factor-1 regulates glutathione peroxidase expression and activity in vascular endothelial cells: Implications for atheroprotective actions of insulin-like growth factor-1. Biochim Biophys Acta (2012) 0.85
The ubiquitin ligase Nedd4 mediates oxidized low-density lipoprotein-induced downregulation of insulin-like growth factor-1 receptor. Am J Physiol Heart Circ Physiol (2008) 0.84
Mechanisms underlying the sympathomimetic cardiovascular responses elicited by gamma-hydroxybutyrate. J Cardiovasc Pharmacol (2004) 0.84
Mechanisms of Cachexia in Chronic Disease States. Am J Med Sci (2015) 0.84
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther (2004) 0.83
Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception. FASEB J (2011) 0.83
Central nervous system Gαi2-subunit proteins maintain salt resistance via a renal nerve-dependent sympathoinhibitory pathway. Hypertension (2012) 0.83
Effect of Hurricane Katrina on chronobiology at onset of acute myocardial infarction during the subsequent three years. Am J Cardiol (2013) 0.83
The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol Metab (2013) 0.83
Central G-alpha subunit protein-mediated control of cardiovascular function, urine output, and vasopressin secretion in conscious Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol (2008) 0.82
Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep (2015) 0.82
Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging. Front Horm Res (2014) 0.81
Centrally administered nociceptin/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors. J Pharmacol Exp Ther (2007) 0.81
Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem (2010) 0.81
Technique and imaging for transthoracic echocardiography of the laboratory pig. Echocardiography (2004) 0.80
Microinjection of glycine into the hypothalamic paraventricular nucleus produces diuresis, natriuresis, and inhibition of central sympathetic outflow. J Pharmacol Exp Ther (2011) 0.80
Skeletal muscle molecular alterations precede whole-muscle dysfunction in NYHA Class II heart failure patients. Clin Interv Aging (2012) 0.80
Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice. J Pharmacol Exp Ther (2008) 0.79
Estrogen regulates insulin-like growth factor 1, platelet-derived growth factor A and B, and their receptors in the vascular wall. Transplantation (2004) 0.79
Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation. Am J Physiol Renal Physiol (2004) 0.78
Endogenous central kappa-opioid systems augment renal sympathetic nerve activity to maximally retain urinary sodium during hypotonic saline volume expansion. Am J Physiol Regul Integr Comp Physiol (2005) 0.78
Mammographically detectable breast arterial calcification and atherosclerosis. Cardiol Rev (2014) 0.76
Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus. J Pharmacol Exp Ther (2004) 0.76
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Mol Cell Biochem (2009) 0.75
Persistent giant U wave inversion with anoxic brain injury. Proc (Bayl Univ Med Cent) (2013) 0.75
Vitamin C and percutaneous coronary intervention. JACC Cardiovasc Interv (2010) 0.75
Coronary angiographic significance of hyperacute ST-T changes associated with regadenoson stress. Proc (Bayl Univ Med Cent) (2013) 0.75
THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES. Trans Am Clin Climatol Assoc (2016) 0.75